Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Doroshow Website

James H. Doroshow, M.D.

Selected Publications

1)  Doroshow JH.
Overcoming resistance to targeted anticancer drugs.
N. Engl. J. Med. 369: 1852-3, 2013.
[Journal]
2)  Kummar S, Allen D, Monks A, Polley EC, Hose CD, Ivy SP, Turkbey IB, Lawrence S, Kinders RJ, Choyke P, Simon R, Steinberg SM, Doroshow JH, Helman L.
Cediranib for metastatic alveolar soft part sarcoma.
J. Clin. Oncol. 31: 2296-302, 2013.
[Journal]
3)  McShane LM, Cavenagh MM, Lively TG, Eberhard DA, Bigbee WL, Williams PM, Mesirov JP, Polley MY, Kim KY, Tricoli JV, Taylor JM, Shuman DJ, Simon RM, Doroshow JH, Conley BA.
Criteria for the use of omics-based predictors in clinical trials.
Nature. 502: 317-20, 2013.
[Journal]
4)  Abaan OD, Polley EC, Davis SR, Zhu YJ, Bilke S, Walker RL, Pineda M, Gindin Y, Jiang Y, Reinhold WC, Holbeck SL, Simon RM, Doroshow JH, Pommier Y, Meltzer PS.
The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology.
Cancer Res. 73: 4372-82, 2013.
[Journal]
5)  Doroshow JH.
Timely completion of scientifically rigorous cancer clinical trials: an unfulfilled priority.
J. Clin. Oncol. 31: 3312-4, 2013.
[Journal]
6)  Wu Y, Lu J, Antony S, Juhasz A, Liu H, Jiang G, Meitzler JL, Hollingshead M, Haines DC, Butcher D, Roy K, Doroshow JH.
Activation of TLR4 is required for the synergistic induction of dual oxidase 2 and dual oxidase A2 by IFN-gamma and lipopolysaccharide in human pancreatic cancer cell lines.
J. Immunol. 190: 1859-72, 2013.
[Journal]
7)  Antony S, Wu Y, Hewitt SM, Anver MR, Butcher D, Jiang G, Meitzler JL, Liu H, Juhasz A, Lu J, Roy KK, Doroshow JH.
Characterization of NADPH oxidase 5 expression in human tumors and tumor cell lines with a novel mouse monoclonal antibody.
Free Radic. Biol. Med. 65: 497-508, 2013.
[Journal]
8)  Doroshow JH, Gaur S, Markel S, Lu J, van Balgooy J, Synold TW, Xi B, Wu X, Juhasz A.
Effects of iodonium-class flavin dehydrogenase inhibitors on growth, reactive oxygen production, cell cycle progression, NADPH oxidase 1 levels, and gene expression in human colon cancer cells and xenografts.
Free Radic. Biol. Med. 57: 162-75, 2013.
[Journal]
9)  Kummar S, Anderson L, Hill K, Majerova E, Allen D, Horneffer Y, Ivy SP, Rubinstein L, Harris P, Doroshow JH, Collins JM.
First-in-Human Phase 0 Trial of Oral 5-Iodo-2-Pyrimidinone-2"-Deoxyribose in Patients with Advanced Malignancies.
Clin. Cancer Res. 19: 1852-7, 2013.
[Journal]
10)  Jaspers JE, Kersbergen A, Boon U, Sol W, van Deemter L, Zander SA, Drost R, Wientjens E, Ji J, Aly A, Doroshow JH, Cranston A, Martin NM, Lau A, O'Connor MJ, Ganesan S, Borst P, Jonkers J, Rottenberg S.
Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors.
Cancer Discov. 3: 68-81, 2013.
[Journal]
Click Here to View Expanded Bibliography.

This page was last updated on 11/10/2013.